Spravato treatment for Boynton Beach — REMS-certified, insurance-covered TRD care.

RECO Integrated Psychiatry is a REMS-certified Spravato (esketamine) site twelve minutes south of Boynton Beach on Federal Highway. The office handles prior authorization for Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans, and dosing sessions are staffed by psychiatric nursing with a psychiatrist on site. Because the induction schedule requires twice-weekly visits for four weeks, drive distance matters — twelve minutes from Renaissance Commons or Ocean Ridge is a cadence that can be sustained without disrupting work or family.

Boynton Beach sits seven miles north of Delray Beach along Federal Highway, and for residents in Renaissance Commons, Ocean Ridge, or Quantum Park, the twelve-minute drive south to RECO Integrated Psychiatry is often shorter than a routine trip to the supermarket. That proximity is not a marketing detail for Spravato treatment — it is a clinical requirement. Every session requires two hours of in-office monitoring and a pre-arranged ride home, logistics that only work when the treatment site sits inside daily life rather than an hour away.

Spravato and the REMS protocol — what treatment actually looks like

Spravato (esketamine) is delivered as a nasal spray that the client self-administers under nursing supervision in the office. Standard dosing for treatment-resistant depression is 56 mg for the first session and 84 mg thereafter, titrated down if tolerability is limiting. The medication itself takes only minutes to administer; the visit is anchored not by the dose but by the two-hour monitoring window that follows.

Under the REMS (Risk Evaluation and Mitigation Strategy) protocol, clinical staff document blood pressure at baseline and again at approximately 40 minutes post-dose, when transient elevation is expected and does not by itself require intervention. Dissociative symptoms are assessed with the CADSS, sedation is monitored, and the client remains observed until vital signs and mental status return to baseline. Driving is prohibited for the remainder of the day, so a ride home must be arranged before the first session.

REMS enrollment and the ongoing documentation burden — dose logs, post-dose assessments, prescriber attestations — are handled by the office as part of the Spravato treatment program. Clients do not manage the paperwork; they arrive, dose, wait, and leave.

The induction and maintenance schedule

The FDA-approved TRD induction schedule is twice weekly for four weeks — eight total sessions — followed by weekly dosing for four weeks and then every one to two weeks for maintenance, adjusted to symptom trajectory. For major depressive disorder with acute suicidal ideation, induction runs twice weekly for four weeks with a separate maintenance decision at the end of that block based on residual symptom burden.

Response timing varies. Many clients notice a shift in depressive symptoms within the first one to two sessions; sustained response typically consolidates across the full eight-session induction rather than after any single dose. PHQ-9 scores are tracked at each visit to document response objectively and to guide the transition from twice-weekly to weekly and then maintenance dosing.

Discontinuation, when it occurs, is done as a taper — extending the interval between sessions — rather than an abrupt stop. Clients who relapse during taper are commonly returned to a shorter interval before attempting to extend again.

Spravato with an oral antidepressant, not instead of one

The FDA approval for esketamine is specifically as adjunctive treatment — used in conjunction with an oral antidepressant, not as a replacement for one. A client arriving with a partial response to sertraline, venlafaxine, or another SSRI or SNRI typically continues that medication through the Spravato induction. Withdrawing an oral agent at the start of esketamine confounds any response signal and is generally avoided.

Clients who have failed multiple antidepressants — the working definition of treatment-resistant depression is inadequate response to two or more antidepressant trials at adequate dose and duration — may benefit from starting or switching an oral agent at the same time as initiating Spravato. Adjunctive strategies with aripiprazole or quetiapine, lithium augmentation, or a class switch to an SNRI are all reasonable depending on history.

The concurrent medication management is handled by the same psychiatry team overseeing the Spravato sessions, not by a separate outside prescriber. That coordination is the point of an integrated program.

Spravato versus IV ketamine and how we choose

Spravato and IV ketamine are related but not interchangeable. Spravato is FDA-approved for TRD and for MDD with acute suicidal ideation and is covered by most commercial insurance plans when the diagnosis is documented. IV ketamine is used off-label for depression and is almost universally cash-pay; there is no insurance pathway of comparable reliability.

Dosing differs. Spravato is fixed at 56 mg or 84 mg intranasally; IV ketamine is dosed by weight — commonly around 0.5 mg/kg over 40 minutes — and can be titrated up or down based on response and tolerability. In-office time is similar: a Spravato visit is roughly two hours end-to-end, and a standard IV ketamine visit runs about the same for a 40-minute infusion plus recovery.

The right choice depends on insurance status, prior response to either agent, tolerability of the intranasal versus intravenous route, and scheduling. The consult at RECO walks through both options honestly rather than defaulting to whichever is in front of the clinician that day.

What to expect on the first visit

The first visit is a psychiatric evaluation, not a dose. The psychiatrist reviews prior antidepressant trials in detail — agent, dose, duration, response, side effects — to confirm the TRD criteria of two or more adequate trials. PHQ-9 and GAD-7 are administered as baseline measures; the C-SSRS or equivalent covers suicidality history for clients being evaluated under the acute-suicidality indication.

REMS enrollment paperwork is completed at the consult, and the ride-home logistics for the first dosing visit are confirmed before leaving. Clients on benzodiazepines, opioids, or stimulants disclose current doses at intake; concurrent controlled substances are not automatically disqualifying, but they change monitoring intensity and may affect same-day dosing decisions.

The first dosing session is scheduled separately from the consult, typically within a week of insurance authorization. Clients are asked not to eat heavily in the two hours before dosing and not to drink fluids in the 30 minutes before the nasal spray to reduce the risk of taste-related nausea.

Insurance and admissions from Boynton Beach

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans, and prior authorization for Spravato under the TRD indication is handled by the office. Most commercial payers require documentation of at least two failed antidepressant trials at adequate dose and duration; the psychiatric evaluation captures that history in the format payers expect.

Admission for Boynton Beach residents is straightforward — the office sits a twelve-minute drive south on Federal Highway or I-95, and the appointment cadence during induction (twice weekly for four weeks) is sustainable at that distance. Clients coming from Renaissance Commons, Hunters Run, Ocean Ridge, Quantum Park, or Briny Breezes have generally reported that the drive is a non-issue by the second week, particularly compared to residential alternatives that would require stepping away from work entirely.

Serving residents of: Renaissance Commons, Ocean Ridge, Quantum Park, Hunters Run, Briny Breezes.